Navigation Links
MedVantx Launches Patient Profile™, A Proprietary Closed-Loop Pharmaceutical Adherence Management Program for Medical Home, Accountable Care and Population Health Management
Date:11/22/2011

SAN DIEGO, Nov. 22, 2011 /PRNewswire/ -- MedVantx, Inc., today announced the deployment of its patent pending Patient Profile™ patient medication and adherence reporting engine across its network of 3,600 high prescribing primary care providers participating in the Company's integrated program of initial free medication therapy, adherence management and home delivery program. This new program utilizes the Company's proprietary automated ATM like sample management system ("MedStart") and an integrated secure web reporting portal to provide physicians visibility to their patients' adherence to chronic medication therapy.  The Platform is designed to help leading medical groups meet the requirements of emerging healthcare reform platforms.

Researchers at Harvard University, Brigham and Women's Hospital and CVS/Caremark announced the results of an important study last week indicating that up to 24% of consumers never fill their initial prescription. "While the results of this study are consistent with previous studies in the area, what is interesting is that prescription abandonment rates appear to be increasing with the growth in electronic prescribing," said Susan Hogue, VP of Managed Care Networks and Clinical Services at MedVantx.  "As Physicians embrace EHR and e-prescribing platforms, they need new tools to help insure medication therapy is initiated and adhered to on an ongoing basis.  Today, physicians have limited access to detailed data about medication samples provided and actual prescriptions filled.  MedVantx has pioneered a program that enables physicians to start all their patients on free prescription medications at the point of care thereby eliminating the potential for abandonment. As a result MedVantx is in a unique position to deliver a complete view of a specific patient's medication program from an initial medication sample to continued fulfillment of chronic medications."

<
'/>"/>
SOURCE MedVantx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MedVantx and Blue Cross & Blue Shield of Rhode Island Partner to Provide Physicians with Integrated Medication Management Platform in Newly Created Patient-Centered Medical Homes
2. MedVantx Honored by Inc. 500/5000 Three Years in a Row
3. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
4. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
5. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
6. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
9. Premier Micronutrient Launches Supplement for Hearing Health
10. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
11. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 21, 2014   BioNano Genomics , ... genomics research centers to purchase an Irys™ System ... National Cancer Institute (NCI), NIH Intramural Sequencing Center (NISC) ... Irys, obtaining a comprehensive view of a genome ... (NGS) does not deliver the scalability or reliability ...
(Date:10/22/2014)... InVivo Therapeutics Holdings Corp. (OTCQB: NVIV) based ... spinal cord injury (SCI) treatment with their novel Neuro-Spinal ... tissue regrowth in the spinal cord area when cells ... approved polymer, the scaffold ultimately breaks down to water ... body. NVIV has recently attracted significant investor attention with ...
(Date:10/22/2014)... 2014  AcelRx Pharmaceuticals, Inc. (NASDAQ: ... IAP310 study have been published in Regional ... journal with broad, multidisciplinary readership. IAP310 was a ... and efficacy of Zalviso, also referred to as ... treatment of post-operative pain in patients following open ...
Breaking Medicine Technology:BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 2InVivo Therapeutics Analyst Coverage Initiated: Analyst Report by BrokerBank Securities, Inc. 3AcelRx Announces Publication of Zalviso Phase 3 Abdominal Trial Results 2
... policy , , ROCHESTER, Minn., ... use of the drug therapy etanercept ineffective in treating alcoholic hepatitis, ... alcohol. The results of the study are published in the December ... , VIDEO ALERT: Additional audio and video ...
... VICL ) announced today the receipt of a $1.0 ... Merck,s planned initiation of a Phase I clinical trial of ... is based on Vical,s DNA gene delivery technology and encodes ... separate license agreement. , , ...
Cached Medicine Technology:Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2
(Date:10/22/2014)... With the Affordable Care Act (ACA) open enrollment period starting ... Research (AIR) finds that three out of four Americans are ... percent say they are not likely or only somewhat likely ... , The AIR survey found wide gaps in Americans’ health ... how much they owe for a routine doctor’s visit. , ...
(Date:10/22/2014)... Losing Weight Your Body’s Way , In a world where ... it certainly can be difficult to choose the right weight ... by doing it the healthy way? Set aside the fads ... body, exercise regularly, and choose foods with the most nutritional ... need to exercise more and eat less. Despite the number ...
(Date:10/22/2014)... Akeso Biomedical, Inc. , a privately held ... infections, microbial biofilms, and chronic wounds, announced that Dr. ... , Dr. Sinskey is a Professor ... of Technology, or MIT. He has been a member ... holds positions as Co-Director of the Malaysia-MIT Biotechnology Partnership ...
(Date:10/22/2014)... By Tara Haelle ... -- Binge drinking among young adult men may lead to ... binge drinking didn,t cause a similar rise in blood pressure ... study. In fact, when young adult women drank lightly or ... half, the study found. "This finding parallels studies in ...
(Date:10/22/2014)... Dennis Thompson HealthDay Reporter ... was diagnosed with Ebola while working for NBC News ... leave the special isolation unit at Nebraska Medical Center in Omaha, ... hospital said Tuesday. A blood test confirmed by the U.S. ... can head home to Providence, R.I., NBC News reported ...
Breaking Medicine News(10 mins):Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 2Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 3Health News:Many Americans Fail to Ask Basic Questions Before Signing Up for Health Insurance, National Survey Finds 4Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3
... in the war on asthma symptom control could be a ... that Mom and Dads leeriness towards their childrens asthma medications ... health risks that outweigh the benefits might explain to ... children with the wheezing, coughing and trouble-breathing disease do not ...
... Consultech Strengthens Omnicom,s Presence in China,s Growing ... ... Omnicom Group Inc.,("Omnicom") (NYSE: OMC ), the leading global ... Services,division ("DAS"), a majority ownership interest in Consultech, a leading,healthcare ...
... The American,Psychiatric Association (APA) applauds the U.S. Food and ... led to the,approval of a new treatment for two ... the approvals are a result of the federal,Best Pharmaceuticals ... that leads to this kind of approval, given that ...
... 180 day shared exclusivity on the product, ... announced today that the Company has received tentative ... manufacture and market,Galantamine Hydrobromide Tablets, 4mg (base), 8mg ... treatment of mild to moderate dementia of,the Alzheimer,s ...
... the best drug treatment for their disease, because family doctors ... in the Archives of Disease in Childhood. , Around ... disease prompts up to a third of children aged between ... researchers used national data to calculate the number of prescriptions ...
... in This Region,Deep Commitment to this Market Evidenced in Opening of ... ... and PHILADELPHIA, Sept. 3 Rohm,and Haas Company (NYSE: ROH ... in India to meet,growing demand for its environmentally advanced products and ...
Cached Medicine News:Health News:Parents' perceptions can hamper kids' asthma care, study finds 2Health News:Parents' perceptions can hamper kids' asthma care, study finds 3Health News:Omnicom Acquires Leading Healthcare Marketing Communications Firm in China 2Health News:Omnicom Acquires Leading Healthcare Marketing Communications Firm in China 3Health News:APA Comments on FDA's First Approval of Medication to Treat Pediatric Schizophrenia and Bipolar Disorder 2Health News:Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis 2Health News:Childhood asthma still inappropriately treated in the UK 2Health News:Rohm and Haas Expands in India 2Health News:Rohm and Haas Expands in India 3Health News:Rohm and Haas Expands in India 4
... precise and accurate Measurements! ,Patients are impressed ... examination when they see the doctor is ... - after only 5 minutes of proper ... proficient in the operation of this instrument ...
Great for small incisions and excision needs...
Ideal for short scleral tunnel and trabecular meshwork incisions...
30 Pre-formed and razor sharp...
Medicine Products: